Modification of precipitated morphine withdrawal syndrome by drugs affecting cholinergic mechanisms.
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001341:Autonomic Nervous System / Q000187:drug effects; D004155:Diphenhydramine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006801:Humans; D007099:Imipramine / Q000494:pharmacology; D008464:Mecamylamine / Q000494:pharmacology; D009020:Morphine / Q000494:pharmacology; D009021:Morphine Dependence; D009270:Naloxone; D018377:Neurotransmitter Agents / Q000502:physiology; D010830:Physostigmine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D011941:Receptors, Adrenergic / Q000187:drug effects; D011950:Receptors, Cholinergic / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000139:chemically induced; D009435:Synaptic Transmission; D014043:Tolazoline / Q000494:pharmacology
D018377:Neurotransmitter Agents; D011941:Receptors, Adrenergic; D011950:Receptors, Cholinergic; D009270:Naloxone; D008464:Mecamylamine; D009020:Morphine; D001285:Atropine; D004155:Diphenhydramine; D010830:Physostigmine; D011433:Propranolol; D014043:Tolazoline; D007099:Imipramine